Form 4: Amneal Pharmaceuticals Director Paul M. Meister Acquires 56,361 Restricted Stock Units

Director Paul M. Meister reports acquisition of 56,361 restricted stock units in Amneal Pharmaceuticals, Inc.

Summary

• On May 2, 2024, Paul M. Meister, a director of Amneal Pharmaceuticals, Inc., acquired 56,361 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Amneal's Class A Common Stock.
• The RSUs vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
• Following the transaction, Meister directly owns 56,361 shares of Class A Common Stock represented by the RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock units acquisition by a director. While insider buying can be seen as positive, this is a grant of restricted stock units, which is part of compensation.

Positives

• The acquisition of restricted stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the restricted stock units is contingent upon future events, specifically the company's annual meeting schedule and the anniversary of the grant date.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's increased stake in the company, which is a common practice in the pharmaceutical industry to align management's interests with those of shareholders.

Stakeholder Impact

• The acquisition of restricted stock units by a director could have a slightly positive impact on shareholder sentiment.

Key Dates